# US 2016/0250183 A1 · PKC Delta Inhibitors for use as Therapeutics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250183 A1
- Document ID: US20160250183A1
- Status: Published application
- Kind: A1
- Application number: 15/148,420
- Filed: 2016-05-06
- Published: 2016-09-01
- Earliest claimed: 2012-09-19
- Assignees: Faller & Williams Technology, LLC
- Inventors: Douglas V. Faller; Robert M. Williams
- Web page: https://patentgrep.com/patent/US20160250183A1

## CPC

- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/404: Indoles, e.g. pindolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D 209/86: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 487/14: Ortho-condensed systems
- G01N 33/5011: {for testing antineoplastic activity}
- C12Y 207/10002: Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
- G01N 2333/91205: Phosphotransferases in general
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Y: ENZYMES

## Abstract

The invention is directed to compounds that are specific inhibitors of PKC delta, and methods and compositions for the treatment and prevention of cancers and other disorders. Compositions comprising compounds of the invention are used to treat cancers such as, for example, carcinoid and neuroendocrine tumors, malignant melanomas, pancreatic, gastrointestinal and lung cancers. Neuroendocrine tumor cell lines of pulmonary and gastrointestinal origin are surprisingly sensitive to PKC delta inhibition by the compounds of the invention. The invention is further directed to methods, compositions and kits containing compounds of the formulas (Ia), (IIa), (IIIa), (IVa), and (V) as disclosed and described in FIGS. 11 and 12.

## Claims

### Claim 1

A method of treating or preventing a disease or disorder associated with aberrant PKC delta activity comprising:
formulating a pharmaceutic composition comprising a compound of the formula:
wherein:
R1 is selected from the group consisting of H and a lower alkyl;
R2 and R3 are each independently selected from the group consisting of H, OH and OR;
A, B, C, D, W, X, Y, and Z are each independently selected from the group consisting of N and CH;
G is selected from the group consisting of O, NR, S, and CH2,
R is selected from the group consisting of H, a lower alkyl and aryl; and
n is an integer selected from the group consisting of 1, 2, 3, and 4;
administering a therapeutically effective amount of the pharmaceutical composition to a patient with the disease or disorder associated with aberrant PKC delta activity.

### Claim 2 (depends on 1)

The method of claim 1, wherein the disease or disorder is a cell proliferative disease, a cancer, a tumor, a benign neoplasm, an allergic disease, an inflammatory disease, or an autoimmune disease.

### Claim 3 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition inhibits PKC delta activity of cells of the patient.

### Claim 4 (depends on 1)

The method of claim 1, wherein cells associated with the disease or disorder have aberrantly increased Ras signaling that is inhibited by administration of the pharmaceutical composition.

### Claim 5 (depends on 1)

The method of claim 1, wherein the disease or disorder is selected from the group consisting of diseases of the central nervous system (CNS), neurodegenerative diseases, vascular diseases, restenosis, musculoskeletal diseases, cardiovascular diseases, stroke, pulmonary diseases, gastric diseases, infectious diseases, fibrotic diseases, chronic kidney disease, liver fibrosis, pulmonary/lung fibrosis, systemic sclerosis, idiopathic pulmonary fibrosis, cystic fibrosis, cirrhosis, endomyocardial fibrosis; mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis, coal workers' pneumoconiosis, nephrogenic systemic fibrosis, Crohn's disease, Keloid, myocardial infarction, scleroderma/systemic sclerosis, post-radiation fibrosis, drug-induced fibrosis and combinations thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition comprises one or more excipients, solvents, diluents, liquid vehicles, dispersions, suspension aids, surface active agents, isotonic agents, thickening agents, emulsifying agents, preservatives, antioxidants, solid binders, lubricants, pharmaceutically acceptable salts and/or combinations thereof.

### Claim 7 (depends on 6)

The method of claim 6, wherein the pharmaceutically acceptable salts are selected from the group consisting of ammonium, calcium, sodium, and combinations thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein R1, R2 and R3 are each independently H or OR, and wherein R is H or CH3.

### Claim 9 (depends on 1)

The method of claim 1, wherein R1, R2 and R3 are each H.

### Claim 10 (depends on 1)

The method of claim 1, wherein A, B, C, D, W, X, Y, and Z are each CH, and G is CH2.

### Claim 11 (depends on 1)

The method of claim 1, wherein n is 1 or 2.

### Claim 12 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered orally, parentally or topically in one or more doses.

### Claim 13 (depends on 1)

The method of claim 1, where the pharmaceutical composition is administered by intravenous injection.

### Claim 14 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of the pharmaceutical composition is that amount effective for killing or inhibiting aberrant cell proliferation.

### Claim 15 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount is from 2 to 500 mg/kg of body weight administered one or more times per day.

### Claim 16 (depends on 1)

The method of claim 1, wherein the patient is a mammal or a human.

### Claim 17

A method of manufacturing a pharmaceutical composition comprising:
synthesizing a compound of the formula:
wherein:
R1 is selected from the group consisting of H and a lower alkyl;
R2 and R3 are each independently selected from the group consisting of H, OH and OR;
A, B, C, D, W, X, Y, and Z are each independently selected from the group consisting of N and CH;
G is selected from the group consisting of O, NR, S, and CH2,
R is selected from the group consisting of H, a lower alkyl and aryl; and
n is an integer selected from the group consisting of 1, 2, 3, and 4; and
formulating the compound as a pharmaceutical composition.

### Claim 18 (depends on 17)

The method of claim 17, wherein R1, R2 and R3 are each independently H or OR, and wherein R is H or CH3.

### Claim 19 (depends on 17)

The method of claim 17, wherein R1, R2 and R3 are each H.

### Claim 20 (depends on 17)

The method of claim 17, wherein A, B, C, D, W, X, Y, and Z are each CH, and G is CH2.

### Claim 21 (depends on 17)

The method of claim 17, wherein n is 1 or 2.

### Claim 22 (depends on 17)

The method of claim 17, wherein formulating comprises adding one or more excipients, solvents, diluents, liquid vehicles, dispersions, suspension aids, surface active agents, isotonic agents, thickening agents, emulsifying agents, preservatives, antioxidants, solid binders, lubricants, pharmaceutically acceptable salts and/or combinations thereof.

### Claim 23 (depends on 22)

The method of claim 22, wherein the pharmaceutically acceptable salts are selected from the group consisting of ammonium, calcium, sodium, and/or combinations thereof.

### Claim 24 (depends on 17)

The method of claim 17, further comprises apportioning the pharmaceutical composition as one or more therapeutically effective amounts for administration to a patient orally, parentally or topically.

### Claim 25 (depends on 24)

The method of claim 24, wherein the one or more therapeutically effective amounts comprises from 2 to 500 mg of compound per kg of body weight of the patient.

### Claim 26 (depends on 25)

The method of claim 25, wherein the patient is a mammal or a human.

### Claim 27

A method comprising:
assessing cells of a patient for aberrant PKC delta activity; and
determining a therapeutically effective amount for inhibiting PKC delta activity of a pharmaceutical composition containing a compound of the formula:
wherein:
R1 is selected from the group consisting of H and a lower alkyl;
R2 and R3 are each independently selected from the group consisting of H, OH and OR;
A, B, C, D, W, X, Y, and Z are each independently selected from the group consisting of N and CH;
G is selected from the group consisting of O, NR, S, and CH2,
R is selected from the group consisting of H, a lower alkyl and aryl; and
n is an integer selected from the group consisting of 1, 2, 3, and 4.

### Claim 28 (depends on 27)

The method of claim 27, wherein R1, R2 and R3 are each independently H or OR, and wherein R is H or CH3.

### Claim 29 (depends on 27)

The method of claim 27, wherein R1, R2 and R3 are each H.

### Claim 30 (depends on 27)

The method of claim 27, wherein A, B, C, D, W, X, Y, and Z are each CH, and G is CH2.

### Claim 31 (depends on 27)

The method of claim 27, wherein n is 1 or 2.

### Claim 32 (depends on 27)

The method of claim 27, wherein the cells are aberrantly proliferating cells.

### Claim 33 (depends on 32)

The method of claim 32, wherein the aberrantly proliferating cells are cancer cells.

### Claim 34 (depends on 32)

The method of claim 32, where the therapeutically effective amount is that amount which inhibits PKC delta activity, inhibits proliferation and/or kills the aberrantly proliferating cells.

### Claim 35 (depends on 27)

The method of claim 27, further comprising administering the therapeutically effective amount of the pharmaceutical composition to the cells of the patient orally, parentally or topically and in one or more doses.

### Claim 36 (depends on 35)

The method of claim 35, where the therapeutically effective amount is from 2 to 500 mg/kg of body weight of the patient and the pharmaceutical composition is administered intravenously in one or more doses per day.
